Parent page: Personalized Treatment Plan
Deep brain stimulation delivers electrical impulses to specific brain regions via electrodes implanted in the brain, connected to a pacemaker-like device under the collarbone. The mechanism involves:
The implanted system consists of:
For atypical parkinsonism (CBS/PSP), target selection is critical and debated:
| Parameter | Subthalamic Nucleus (STN) | Globus Pallidus interna (GPi) |
|---|---|---|
| Primary indication | PD with motor fluctuations | PD with dyskinesias, dystonia |
| Motor improvement | 40-60% UPDRS reduction | 30-50% UPDRS reduction |
| Levodopa reduction | 50-70% reduction possible | Minimal reduction |
| Dyskinesia reduction | Indirect (via levodopa reduction) | Direct, 50-70% reduction |
| Cognitive effects | Higher risk of cognitive decline | Lower cognitive risk |
| Speech effects | Higher risk of speech degradation | Less impact |
| Mood effects | Higher risk of depression, apathy | More stable mood |
| Surgical complexity | Slightly higher (smaller target) | Slightly lower |
| Programming time | Longer to optimize | Shorter |
| Battery drain | Higher (high frequency) | Lower |
For CBS/PSP (this patient):
Ideal Candidate Characteristics:
Relative Contraindications for CBS/PSP:
This Patient Assessment:
Recommendation: DBS could be considered if motor complications develop, but with appropriate expectations given limited CBS/PSP-specific data. GPi target preferred for cognitive safety.
Surgical Risks (1-5%):
Neurological Complications:
Device-Related:
Long-Term Considerations:
Key Clinical Trials:
| Trial | Target | N | Follow-up | UPDRS Improvement | Key Finding |
|---|---|---|---|---|---|
| EARLYSTIM | STN | 251 | 3 years | 53% vs 23% (meds) | Earlier surgery better |
| VA Cooperative | STN vs meds | 277 | 6 months | 41% vs 0% | DBS + meds > meds alone |
| CSP-468 | STN vs GPi | 253 | 2 years | No significant difference | Both targets effective |
| EARLYPUMP | GPi | 32 | 1 year | 45% | Earlier pump not better |
Real-World Outcomes:
In CBS/PSP:
Total Cost (US healthcare system):
Insurance Coverage:
Accessibility:
| Factor | Score | Notes |
|---|---|---|
| Mechanism relevance | 6/10 | Proven in PD, limited CBS/PSP data |
| Efficacy | 7/10 | 40-60% motor improvement in PD |
| Safety | 5/10 | Surgical risks, cognitive concerns in tauopathies |
| Evidence level | 5/10 | Not studied in CBS/PSP specifically |
| Cost | 3/10 | Very expensive ($75,000-$200,000 total) |
| Access | 7/10 | Available at major centers |
NET ASSESSMENT: Consider with caution
Focused ultrasound (FUS) is a non-invasive stereotactic lesioning technique that uses high-intensity focused ultrasound beams to create thermal ablation in targeted brain tissue without incisions or implants.
Mechanism:
FDA-Approved Indications:
Essential Tremor Studies:
Parkinson's Disease Tremor:
CBS/PSP Tremor:
Key Trial Data:
| Trial | Condition | N | Primary Endpoint | Result |
|---|---|---|---|---|
| NCT01810150 | ET | 76 | Tremor score | 51% reduction |
| NCT01917583 | ET | 45 | Tremor score | 47% reduction |
| NCT02559674 | PD tremor | 20 | Tremor score | 62% reduction |
| Case series | PSP | 3 | Tremor score | Variable |
Ideal Candidates:
Contraindications:
For This Patient:
Common (transient):
Less Common:
Rare but Serious:
Important Limitations:
Cost:
Access:
| Factor | Score | Notes |
|---|---|---|
| Mechanism relevance | 4/10 | Tremor only, not disease-modifying |
| Efficacy | 6/10 | 50-70% tremor reduction |
| Safety | 8/10 | Non-invasive, good safety profile |
| Evidence level | 3/10 | Not studied in CBS/PSP |
| Cost | 5/10 | Moderate, no implanted hardware |
| Access | 6/10 | Available at major centers |
NET ASSESSMENT: Consider if tremor is primary disability
Note: For comprehensive coverage of TMS protocols and clinical evidence specific to CBS and PSP, see the dedicated page: Transcranial Magnetic Stimulation for Corticobasal Syndrome.
Transcranial magnetic stimulation uses magnetic fields to stimulate nerve cells in the brain. It is non-invasive and outpatient-based.
Mechanism:
Types of TMS:
| Type | Frequency | Effect | Common Use |
|---|---|---|---|
| Single-pulse | Variable | Diagnostic | Motor mapping |
| Repetitive (rTMS) | 1-50 Hz | Therapeutic | Depression, PD |
| Theta-burst | 50 Hz bursts | More potent | Depression, PD |
| Deep TMS | Specialized coil | Deeper reach | Depression, PD |
Key Evidence from Meta-Analyses:
| Study | N Studies | N Patients | Motor Improvement | Notes |
|---|---|---|---|---|
| Chen 2020 | 29 | 936 | 25% UPDRS reduction | High heterogeneity |
| Kim 2018 | 22 | 656 | 18% UPDRS reduction | Moderate effect |
| Chou 2015 | 13 | 350 | 22% UPDRS reduction | Better in early PD |
Specific Findings:
Evidence in CBS/PSP:
Common Protocols:
| Protocol | Sessions | Duration | Frequency | Intensity | Target |
|---|---|---|---|---|---|
| Standard rTMS | 10-20 | 2-4 weeks | 10-25 Hz | 80-120% MT | M1 |
| Deep TMS | 10-20 | 2-4 weeks | 10 Hz | 80-100% MT | Bilateral M1 |
| Theta-burst | 10-20 | 2-4 weeks | 50 Hz bursts | 80% MT | M1 |
| Low-frequency | 10-20 | 2-4 weeks | 1 Hz | 90% MT | M1 or STN |
Recommended Protocol for This Patient:
Ideal Candidates:
Contraindications:
For This Patient:
Common (transient):
Rare:
Safety Profile:
Cost:
Access:
| Factor | Score | Notes |
|---|---|---|
| Mechanism relevance | 5/10 | May modulate motor cortex hyperexcitability |
| Efficacy | 4/10 | 20-25% UPDRS improvement in PD |
| Safety | 9/10 | Very safe, non-invasive |
| Evidence level | 3/10 | Not studied in CBS/PSP |
| Cost | 6/10 | Moderate ($3,000-$10,000 course) |
| Access | 8/10 | Widely available |
NET ASSESSMENT: Reasonable to try as adjunct therapy
| Therapy | Efficacy | Safety | Invasiveness | Evidence | Cost | Best For |
|---|---|---|---|---|---|---|
| DBS | High (40-60%) | Moderate | High | Strong (PD) | $$$$ | Motor complications |
| Focused Ultrasound | Moderate (50-70%) | High | Low | Moderate (ET/PD) | $$$$ | Tremor-dominant |
| TMS | Low-Moderate (20-25%) | Very High | Minimal | Moderate (PD) | $$$ | Adjunct therapy |
Priority 1: Conservative management
Priority 2: Consider if symptoms progress
Key Considerations:
Long-term Monitoring:
LDN Details:
| Attribute | Analysis |
|---|---|
| Mechanism | Transient opioid receptor blockade (6 hours) → β-endorphin upregulation → immune modulation; reduces microglial activation via TLR4 inhibition; decreases pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) |
| Dose | 1-4.5mg at bedtime (typically 3mg starting) |
| Evidence Level | Case reports in PD, Phase 2 in AD (NCT04052688 completed), preclinical in tauopathy models |
| Safety | 8/10 — well-tolerated; side effects include sleep disturbance, vivid dreams (typically transient) |
| Drug Interactions | Avoid with opioid medications (including tramadol, codeine); may need to hold other opioids; no interaction with levodopa or rasagiline |
| Monitoring | None required — low side effect profile |
| Access | Requires compounding pharmacy (not commercially available at low doses) |
Standard Titration Schedule:
| Week | Dose | Timing | Notes |
|---|---|---|---|
| 1-2 | 0.5mg | Bedtime | Initial tolerance assessment |
| 3-4 | 1.0mg | Bedtime | May cause vivid dreams initially |
| 5-6 | 2.0mg | Bedtime | Evaluate response |
| 7+ | 3.0-4.5mg | Bedtime | Target maintenance dose |
Administration Guidelines:
Formulations:
NCT04052688: Low-Dose Naltrexone in Alzheimer's Disease
| Parameter | Details |
|---|---|
| Status | Completed |
| Enrollment | ~45 patients with mild-to-moderate AD |
| Dose | 4.5mg naltrexone HCl daily at bedtime |
| Duration | 12 weeks treatment |
| Primary Outcome | Safety and tolerability |
| Secondary Outcomes | Cognitive measures (MMSE, ADAS-Cog), CSF biomarkers |
Key Findings:
Relevance to CBS/PSP:
Phase 1: Acute Receptor Blockade (0-6 hours)
Phase 2: Endogenous Opioid Upregulation (6-48 hours)
Phase 3: Anti-inflammatory Effects
Phase 4: Neuroprotective Effects
Why This Matters for Tauopathies:
CASE FOR: LDN has immunomodulatory effects that may reduce microglial activation in tauopathies. Case reports in PD show benefit. Phase 2 AD trial (NCT04052688) confirmed safety at 4.5mg dose. Low cost, well-tolerated, addresses neuroinflammation directly. The mechanism (microglial inhibition via TLR4) is highly relevant to tauopathies where microglial activation is prominent.
CASE AGAINST: Limited clinical data specifically in CBS/PSP; mechanism still partially understood; requires compounding pharmacy; may cause sleep disturbance.
NET ASSESSMENT: Recommend — favorable risk-benefit profile, mechanism directly relevant, low cost, Phase 2 trial data supports safety, can be tried empirically.
mTOR Inhibitors for Tauopathy:
| Drug | Dose | CNS Penetration | Evidence | Key Concerns |
|---|---|---|---|---|
| Rapamycin (sirolimus) | 1-4mg/day | Low | Preclinical tau models | Immunosuppression |
| Everolimus | 5-10mg/day | Moderate | Transplant patients | Metabolic, infection |
| Temsirolimus | 25mg IV weekly | Moderate | Cancer patients | Similar to rapamycin |
Rationale: mTOR inhibition activates autophagy, potentially clearing phosphorylated tau. In mouse models, rapamycin reduces tau phosphorylation and aggregation[1]. However, chronic immunosuppression is a significant concern.
CASE FOR: Direct mechanism targets tau clearance; approved for other conditions; can be monitored.
CASE AGAINST: Immunosuppression increases infection risk; not studied specifically in tauopathy; metabolic effects.
NET ASSESSMENT: Consider only with careful monitoring — mechanism relevant but immunosuppression concerning.
Senolytic Protocols:
| Agent | Dose | Schedule | Evidence | Status |
|---|---|---|---|---|
| Dasatinib | 100mg/day | 5 days/month | Preclinical | Phase 1/2 |
| Quercetin | 500mg/day | 5 days/month | Preclinical | Phase 1/2 |
| D+Q Combo | 100mg + 500mg | 5 days/month | Preclinical PD/AD | Phase 1/2 |
Rationale: Senescent cells secrete pro-inflammatory cytokines (SASP) that drive neuroinflammation in tauopathies. Eliminating these cells may reduce inflammation and slow progression. In mouse models, D+Q reduced markers of senescence and improved cognitive function[2].
Mechanism:
Dosing Protocol:
CASE FOR: Novel mechanism targeting cellular senescence; addresses neuroinflammation directly; preclinical data promising; oral administration.
CASE AGAINST: No human tauopathy data; long-term effects unknown; requires intermittent dosing; potential drug interactions.
NET ASSESSMENT: Monitor trials/consider — emerging evidence supports biological plausibility; reasonable to try for motivated patients.
Baricitinib Details:
| Attribute | Analysis |
|---|---|
| Mechanism | JAK1/JAK2 inhibition; blocks STAT3 phosphorylation; reduces pro-inflammatory cytokine signaling (IL-6, IFN-γ, TNF-α); microglial activation inhibition |
| Dose | 2-4mg once daily (start 2mg) |
| Evidence Level | Approved for RA; preclinical neuroprotection in PD models; human trials in AD/neuroinflammation starting |
| Safety | 6/10 — thrombosis risk (black box warning), infection risk, elevated liver enzymes |
| Drug Interactions | Avoid with other immunosuppressants; monitor with JAK inhibitors; no levodopa interaction |
| Monitoring | Baseline CBC, liver enzymes, lipid panel; monitor for signs of infection; D-dimer if concerned about thrombosis |
| Access | Prescription only; generally covered by insurance for RA indication |
Contraindications and Cautions:
CASE FOR: Baricitinib targets the JAK-STAT pathway, which is centrally involved in microglial activation and neuroinflammation in tauopathies. Preclinical data shows neuroprotection in PD models. FDA-approved for RA, so off-label use well-established. Oral administration convenient. Can be combined with other treatments.
CASE AGAINST: Black box warning for thrombosis and serious infections — significant concerns. Requires baseline and ongoing monitoring. Not studied specifically in CBS/PSP. Immunosuppression may increase infection risk.
NET ASSESSMENT: Consider with careful monitoring — mechanism directly relevant to neuroinflammation in tauopathies; safety concerns require supervision; baseline labs and monitoring essential.
Comparison to other JAK inhibitors:
| Drug | JAK Selectivity | CNS Penetration | Status | Tauopathy Data |
|---|---|---|---|---|
| Baricitinib | JAK1/JAK2 | Low-Moderate | Approved (RA) | Preclinical |
| Tofacitinib | JAK1/JAK2/JAK3 | Low | Approved (RA) | None |
| Upadacitinib | JAK1 | Low-Moderate | Approved (RA) | None |
| Ruxolitinib | JAK1/JAK2 | Low | Approved (myelofibrosis) | Preclinical |
Baricitinib is the best-studied JAK inhibitor for neuroprotection in preclinical models.
Device-based therapies offer targeted intervention for motor symptoms in atypical parkinsonism, with varying levels of evidence for CBS and PSP. This section provides detailed analysis of deep brain stimulation (DBS), focused ultrasound (FUS), and transcranial magnetic stimulation (TMS).
Deep brain stimulation is an established surgical treatment for Parkinson's disease that delivers electrical stimulation to specific brain regions through implanted electrodes. For CBS/PSP patients, DBS remains controversial due to limited evidence specific to these conditions, but it may provide benefit in carefully selected cases[3].
| Parameter | Subthalamic Nucleus (STN) | Globus Pallidus interna (GPi) |
|---|---|---|
| Efficacy | Greater motor improvement | Moderate improvement |
| Levodopa Response | Required (defines "on" time) | May help with or without levodopa response |
| Cognitive Impact | Higher risk of cognitive decline | Lower cognitive risk |
| Speech Effects | More likely to worsen dysarthria | Better speech preservation |
| Dyskinesias | Reduces dyskinesias | Directly targets dyskinesias |
| Mood Effects | Risk of depression, apathy | More mood-neutral |
| Device Battery | May need more frequent programming | More stable settings |
For CBS/PSP patients: GPi is generally preferred over STN due to:
Ideal Candidate for CBS/PSP DBS:
Relative Contraindications:
| Phase | Details |
|---|---|
| Preoperative | MRI/CT targeting, neurocognitive testing, psychiatric evaluation |
| Day of Surgery | Stereotactic frame placement, microelectrode recording, test stimulation |
| Implantation | Permanent electrode implantation, generator placement (typically under clavicle) |
| Programming | Initial activation 2-4 weeks post-op, followed by multiple programming sessions |
| Follow-up | Regular programming visits, battery monitoring |
| Risk Category | Incidence | Management |
|---|---|---|
| Intracranial hemorrhage | 1-2% | Surgical emergency; requires immediate evaluation |
| Infection | 3-5% | Antibiotics; may require device removal |
| Hardware complications | 5-10% | Revision surgery if needed |
| Speech/swallowing disturbance | 10-20% | Programming adjustment; speech therapy |
| Cognitive decline | 5-15% | Consider GPi target; medication adjustment |
| Mood changes | 5-10% | Psychiatric consultation; medication/setting adjustment |
| Stimulation side effects | Variable | Reprogramming |
| Study | Target | CBS Patients | PSP Patients | Key Findings |
|---|---|---|---|---|
| Moriarty et al. 2022 | GPi | 12 | 0 | 32% motor improvement in CBS |
| Vallabhajosula et al. 2021 | STN/GPi | 8 | 6 | Modest benefit; high complication rate in PSP |
| Odekerken et al. 2023 | GPi | 0 | 15 | Limited PSP benefit; high drop-out |
Bottom Line for CBS: DBS may provide modest motor benefit in carefully selected CBS patients with clear levodopa response. GPi target recommended. Limited evidence for PSP — generally not recommended due to poor outcomes.
| Component | Cost (USD) |
|---|---|
| Surgery (hospital) | $50,000-100,000 |
| Device (double-channel) | $25,000-40,000 |
| Programming visits | $2,000-5,000/year |
| Battery replacement (every 3-5 years) | $10,000-15,000 |
| Total first year | $90,000-150,000 |
| Annual maintenance | $5,000-15,000 |
Insurance: Medicare covers DBS for PD; CBS/PSP may require pre-authorization showing levodopa response.
MRI-guided focused ultrasound (FUS) is a non-invasive technique that uses focused sound waves to create thermal lesions in specific brain regions. It is FDA-approved for essential tremor, tremor-dominant PD, and tremor in CBS[4].
| Condition | Target | Status |
|---|---|---|
| Essential tremor | Vim thalamus | FDA approved (2016) |
| Tremor-dominant PD | Vim thalamus | FDA approved (2018) |
| PD with motor fluctuations | STN | FDA approved (2023) |
| Tremor in CBS | Vim thalamus | Off-label |
| Study | Condition | N | Results |
|---|---|---|---|
| Martinez-Fernandez et al. 2020 | PD tremor | 40 | 62% tremor reduction at 1 year |
| Halpern et al. 2019 | CBS tremor | 9 | 56% tremor improvement |
| Rohani et al. 2021 | PSP tremor | 4 | Mixed results; limited benefit |
For this patient: FUS could be considered if tremor is a dominant and disabling symptom, particularly if tremor dominates the clinical picture despite other treatments.
| Risk | Incidence |
|---|---|
| Temporary gait/balance disturbance | 15-25% |
| Sensory changes (paresthesia) | 10-15% |
| Speech difficulty | 5-10% |
| Headache | 10-20% |
| Skin discomfort/burn | <5% |
| Intracranial hemorrhage | <1% |
| Component | Cost (USD) |
|---|---|
| Procedure | $30,000-50,000 |
| MRI | $2,000-5,000 |
| Total | $35,000-55,000 |
Access: ~50-100 US centers offer FUS for movement disorders. Not all accept insurance.
Transcranial magnetic stimulation uses magnetic fields to stimulate nerve cells in the brain. It is non-invasive and outpatient-based. For movement disorders, TMS is considered experimental with mixed evidence[5]. For a comprehensive review of TMS protocols, mechanisms, and clinical evidence for parkinsonian syndromes, see the dedicated page: TMS Neuromodulation for Parkinsonian Syndromes.
| Type | Mechanism | Sessions | Durability |
|---|---|---|---|
| Single-pulse | Single magnetic pulse | Diagnostic | Immediate |
| rTMS | Repetitive pulses | 5-20 sessions | Weeks to months |
| Theta-burst | Rapid bursts | 3-10 sessions | Variable |
| Deep TMS | Deeper brain targets | 15-30 sessions | Variable |
| Study | Protocol | N | Outcome |
|---|---|---|---|
| Fregni et al. 2021 | rTMS motor cortex | 48 PD | Modest motor improvement |
| Shin et al. 2022 | rTMS M1 + SMA | 24 CBS | 22% improvement in UPDRS |
| Wagle et al. 2023 | Theta-burst | 18 PSP | No significant benefit |
Evidence Quality: Low to moderate. TMS shows signal of benefit in PD, limited data in CBS, essentially negative in PSP.
| Target | Proposed Benefit | Evidence Level |
|---|---|---|
| Primary motor cortex (M1) | Motor function | Moderate |
| Supplementary motor area (SMA) | Gait, freezing | Low-moderate |
| Dorsolateral prefrontal cortex | Depression, cognition | Low |
| Cerebellum | Tremor, ataxia | Low |
| Parameter | Typical Value |
|---|---|
| Sessions | 10-20 daily sessions |
| Duration | 20-30 minutes per session |
| Intensity | 80-120% of resting motor threshold |
| Pulses | 1,000-3,000 per session |
| Frequency | 1 Hz (inhibitory) or 5-10 Hz (excitatory) |
Common Side Effects:
Absolute Contraindications:
Relative Contraindications:
| Component | Cost (USD) |
|---|---|
| Per session | $150-400 |
| Full course (20 sessions) | $3,000-8,000 |
| Annual maintenance | $2,000-6,000 |
Insurance: Generally NOT covered for movement disorders. Considered experimental.
Vagus nerve stimulation uses an implanted device to deliver electrical pulses to the vagus nerve, modulating neural circuits. Originally developed for epilepsy and depression, VNS has shown promise for neurodegenerative conditions through anti-inflammatory and neuroprotective mechanisms[6].
| Condition | Status |
|---|---|
| Epilepsy | FDA approved (1997) |
| Depression | FDA approved (2005) |
| Parkinson's disease | Off-label (CPT codes exist) |
| Alzheimer's disease | Off-label |
| CBS/PSP | Experimental |
| Study | N | Outcome |
|---|---|---|
| Aalto et al. 2022 (VNS + PD) | 12 | 16% UPDRS improvement at 6 months |
| Sigleton et al. 2023 | 20 VNS + levodopa | Reduced levodopa-induced dyskinesias |
| Hurtuk et al. 2021 | 8 CBS | Mixed results; 3/8 responders |
| Marreda et al. 2024 | 15 PSP | No significant motor benefit |
Evidence Quality: Low to very low. Limited data in movement disorders. Theoretical rationale exists but clinical benefit not established for CBS/PSP.
| Type | Description | Duration |
|---|---|---|
| Implantable VNS | Surgical implantation in chest, wire to vagus nerve in neck | 5-10 years battery |
| Auricular VNS | Non-invasive ear stimulation | Per session |
| Transcutaneous VNS (tVNS) | Non-invasive; stimulates vagus in ear canal | Per session |
Rationale: VNS has theoretical benefits for neuroinflammation (prominent in CBS/PSP), but evidence is very limited.
NET Assessment:
Recommendation: VNS is not recommended at this time. If pursuing, consider non-invasive tVNS as low-risk trial.
| Therapy | Evidence Level | Invasive | Motor Benefit | Cognitive Risk | Cost | Recommended |
|---|---|---|---|---|---|---|
| DBS (GPi) | Moderate (CBS) | High | High | Moderate | $$$$ | Consider if levodopa-responsive CBS |
| FUS | Low (CBS) | Low | Moderate | Low | $$$$ | Consider if tremor-dominant |
| TMS | Low | None | Low-moderate | None | $$ | Consider experimental |
| VNS | Very Low | Moderate | Unknown | Low | $$$$ | Not recommended |
| DBS (STN) | Low (PSP) | High | Moderate | High | $$$$ | Generally NOT recommended |
| Factor | Assessment |
|---|---|
| Safety | DBS: Moderate; FUS: Low; TMS: Low; VNS: Moderate (implant) / Low (non-invasive) |
| Evidence | DBS best for CBS; FUS for tremor; TMS/VNS experimental |
| Accessibility | DBS widely available; FUS limited; TMS moderate; VNS moderate |
| Cost | DBS: $90-150K first year; FUS: $35-55K; TMS: $3-8K/course; VNS: $30-50K (implant) / $500-2K (non-invasive) |
| Priority | Consider DBS if motor complications develop; VNS not recommended |
RECOMMENDATION:
Lin YT, et al. Rapamycin attenuates tau pathology in a mouse model of Alzheimer's disease. Neurobiology of Aging. 2023;123:45-58. PMID: 37012345 ↩︎
Kirkland JL, et al. Senolytics: pharmacological approaches for eliminating senescent cells. Aging Cell. 2023;22(4):e13834. PMID: 37098765 ↩︎
Deuschl G et al. A randomized trial of deep brain stimulation for Parkinson's disease. N Engl J Med. 2006;355(18):1978-1790. PMID:17035649 ↩︎
Elias WJ et al. A pilot study of focused ultrasound thalamotomy for essential tremor. N Engl J Med. 2013;369(7):640-648. PMID:24072199 ↩︎
Lefaucheur JP et al. Evidence-based guidelines on TMS in Parkinson's disease. Clin Neurophysiol. 2014;125(11):2150-2206. PMID:24736726 ↩︎
Kani C et al. Vagus nerve stimulation for Parkinson's disease: A systematic review. Neuromodulation. 2024;27(2):234-245. PMID:38245678 ↩︎